ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT

DISEASE Gallbladder adenocarcinoma
NAME Li He, Mei-Lan
DATE OF BIRTH 15 September 1947
SEX Female
MEDICAL RECORD # 47781726

PHYSICIAN

ORDERING PHYSICIAN Chen, Ming-Huang
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN ID MLLH 9/15/1947
SPECIMEN TYPE Blood
DATE OF COLLECTION 09 November 2021
SPECIMEN RECEIVED 11 November 2021

Biomarker Findings

Blood Tumor Mutational Burden - 8 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Cannot Be Determined

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

STK11 splice site 863-80_880del98
DNMT3A P904L
RB1 splice site 2211+1G>A
TP53 R175H

0 Therapies with Clinical Benefit
0 Therapies with Resistance
4 Clinical Trials

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Blood Tumor Mutational Burden - 8 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**
Tumor Fraction - Cannot Be Determined	**Tumor fraction is an estimate of the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample based on observed aneuploid instability.**

GENOMIC FINDINGS		VAF %	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
STK11 -	splice site 863-80_880del98	0.52%	None	None
4 Trials see p. 9				

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

DNMT3A - P904L p. 6

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1236318-01 VAF%
Blood Tumor Mutational Burden		8 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Cannot Be Determined
STK11	splice site 863-80_880del98	0.52%
DNMT3A	P904L	0.41%
RB1	splice site 2211+1G>A	2.0%
TP53	R175H	0.68%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
8 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-2] and anti-PD-1[3] therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb[1]. In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[4].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)[5-7]. Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2021). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study[8], TMB-high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB-high tumors experienced numerically longer OS compared with patients with TMB-low tumors (11.5 vs. 8.4 months, adjusted HR=0.65)[9].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[10-11] and cigarette smoke in lung cancer[12-13], treatment with temozolomide-based chemotherapy in glioma[14-15], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[16-20], and microsatellite instability (MSI)[16,19-20]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-3]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Cannot Be Determined

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with high tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results[21]. However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[22-27].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[28]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[29], Ewing sarcoma and osteosarcoma[30], prostate cancer[25], breast cancer[31], leiomyosarcoma[32], esophageal cancer[33], colorectal cancer[34], and gastrointestinal cancer[35].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[36], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[37-38]. However, the tumor fraction estimate in this sample could not be determined with confidence.

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
STK11

ALTERATION
splice site 863-80_880del98

TRANSCRIPT ID
NM_000455

CODING SEQUENCE EFFECT
863-80_880del98

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Increased mTOR signaling is present in LKB1-deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations[39-43]. Case studies have reported PRs for 2 patients with STK11-mutated pancreatic cancer following treatment with the mTOR inhibitor everolimus[44], with 1 PR observed in a PJS patient for 9 months until progression[44]. However, retrospective analysis of a Phase 2 trial for patients with endometrial carcinoma found LKB1 (STK11) protein levels were not significantly correlated with response to everolimus treatment[45]. In one preclinical study, STK11 loss was associated with sensitivity to combination treatment including an SRC inhibitor[46]; however, the clinical relevance of these findings has not been established.

— Potential Resistance —

STK11 alteration is associated with poorer response to immune checkpoint inhibitors for patients with NSCLC, including those with tumors harboring co-occurring KRAS mutation[47-59] .

FREQUENCY & PROGNOSIS

STK11 mutations have been reported in 2.4% of biliary tract carcinomas analyzed in the COSMIC database (Mar 2021)[7]. STK11 mutation or loss have also been reported in biliary tract adenocarcinomas in the literature[60-62]. One study reported an association between lower STK11 protein expression and reduced survival OS for patients with gallbladder carcinoma[63]. Loss of STK11 protein expression in intrahepatic cholangiocarcinoma has been reported as an independent predictor of shorter OS and time to recurrence[64].

FINDING SUMMARY

The serine/threonine kinase STK11 (also called LKB1) activates AMPK and negatively regulates the mTOR pathway in response to changes in cellular energy levels[39]. LKB1 acts as a tumor suppressor in cancer, as loss of function promotes proliferation and tumorigenesis[46,65]. Alterations such as seen here may disrupt STK11 function or expression[66-77].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in STK11 underlie Peutz-Jeghers syndrome (PJS), a rare autosomal dominant disorder associated with a predisposition for tumor formation[78]. This disorder has an estimated frequency between 1:29,000 and 1:120,000, although reported rates in the literature vary greatly[78-80]. Although gastrointestinal tumors are the most common malignancies associated with PJS, patients also exhibit an 18-fold increased risk of developing other epithelial cancers[78-80], and individuals with this syndrome have a 30-50% risk of developing breast cancer[78,80]. Given the association with PJS, in the appropriate clinical context testing for the presence of germline mutations in STK11 is recommended.

GENE
DNMT3A

ALTERATION
P904L

TRANSCRIPT ID
NM_022552

CODING SEQUENCE EFFECT
2711C>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors.

FREQUENCY & PROGNOSIS

DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2021)[5-6]. Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2021).

FINDING SUMMARY

The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation[81-82]. The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor[83-88]. Alterations such as seen here may disrupt DNMT3A function or expression[89-92].

POTENTIAL CLONAL HEMATOPOIESIS

IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[93-98]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[93-94]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[99]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[97,100-101]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
RB1

ALTERATION
splice site 2211+1G>A

TRANSCRIPT ID
NM_000321

CODING SEQUENCE EFFECT
2211+1G>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of limited clinical data[102] and strong preclinical data[103-105], RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer. It should be noted that a trial of the Aurora kinase A inhibitor alisertib in advanced prostate cancer did not find an association between RB1 deletion and clinical benefit[106]. Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL-2 family members[107] and activation of the NOTCH pathway[108].

— Potential Resistance —

Rb inactivation may predict resistance to CDK4/6 inhibitors such as palbociclib, abemaciclib, and ribociclib, which act upstream of Rb[109-118].

— Nontargeted Approaches —

Loss of Rb function has been associated with increased sensitivity to cytotoxic agents and chemotherapeutics in both preclinical studies and in patients with bladder or breast cancer[119-120].

FREQUENCY & PROGNOSIS

RB1 mutations were found in 3.8% of gallbladder adenocarcinoma cases (COSMIC, Feb 2021)[7]. In one study RB1 mutations were reported in 6% of 53 gallbladder adenocarcinoma samples analyzed[121]. Loss of RB1 was detected in one of eight patients with gallbladder carcinoma in one study[122]. The prognostic significance of RB1 mutation in gallbladder carcinoma has not been extensively studied (PubMed, Jul 2021).

FINDING SUMMARY

RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle[120,123]. Alterations such as seen here may disrupt RB1 function or expression[124-130].

POTENTIAL GERMLINE IMPLICATIONS

Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year[131]. Germline mutations in RB1 account for approximately 40% of RB tumors[132] and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma[133-134]. In the appropriate clinical context, germline testing of RB1 is recommended.

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TP53

ALTERATION
R175H

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
524G>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[135-138], or p53 gene therapy and immunotherapeutics such as SGT-53[139-143] and ALT-801[144]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild-type[145]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[146]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[147]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[148]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel[149]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations[150]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[143]. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutated, but not TP53-wild-type, breast cancer xenotransplant mouse model[151]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR-246[152-154]. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[155]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[156-157]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[158-159]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25-63% of gallbladder carcinomas and 10-61% of cholangiocarcinomas[8,160-168]. TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%)[163]. TP53 alteration and inactivation were shown to be early and common events in gallbladder carcinogenesis[169]. Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20–62% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas[170-172]. Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting[173-181]. Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers[182-183]; however, another study did not find such a correlation[175].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[184]. Alterations such as seen here may disrupt TP53 function or expression[185-189].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2021)[190]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[191-193], including sarcomas[194-195]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[196] to 1:20,000[195]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[197]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[93-98]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[93-94]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[99]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[97,100-101]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

CLINICAL TRIALS

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
STK11

ALTERATION
splice site 863-80_880del98

RATIONALE
Increased mTOR signaling is present in LKB1-deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations.

NCT03065062

PHASE 1

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

TARGETS
PI3K-alpha, PI3K-gamma, mTORC1, mTORC2, CDK4, CDK6

LOCATIONS: Massachusetts

NCT02159989

PHASE 1

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

TARGETS
PIGF, VEGFA, VEGFB, mTORC1, mTORC2

LOCATIONS: Texas

NCT03017833

PHASE 1

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

TARGETS
mTORC1, mTORC2

LOCATIONS: Texas

NCT03430882

PHASE 1

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

TARGETS
mTORC1, mTORC2

LOCATIONS: Texas

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

BRCA2 I2194T	***CHEK2*** G176R	***CUL3*** Y74F	***EPHA3*** P213L
FANCC R532K	***FUBP1*** Q333E	***GNAS*** E105K	***JUN*** M260I
PTEN M205V	***SETD2*** L886F	***SPEN*** S2292L	***VEGFA*** W187S

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*C11orf30* (EMSY)	*C17orf39* (GID4)	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*
CCND1	*CCND2*	*CCND3*	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*
CD274 **(PD-L1)**	*CDC73*	***CDH1***	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*
CDKN2A	*CDKN2B*	*CDKN2C*	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***
CSF1R	*CSF3R*	*CTCF*	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*
DAXX	*DDR1*	***DDR2*** **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EP300*
EPHA3	*EPHB1*	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***
ESR1 **Exons 4-8**	*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FAM46C*	*FANCA*
FANCC	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*
FGF23	*FGF3*	*FGF4*	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*
FLCN	*FLT1*	***FLT3*** **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*
GNA11 **Exons 4, 5**	*GNA13*	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3F3A*	*HDAC1*	*HGF*
HNF1A	***HRAS*** **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*
INPP4B	*IRF2*	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*
KDM5C	*KDM6A*	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*
MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11A*	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TERC** ncRNA	***TERT**** **Promoter**	*TET2*
TGFBR2	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*	*TYRO3*
U2AF1	***VEGFA***	*VHL*	*WHSC1*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating-tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from observed aneuploid instability in the sample.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.
11. Alterations reported may include somatic (not

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.

12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.1.1

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
6. Gao J, et al. Sci Signal (2013) pmid: 23550210
7. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
8. Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846
9. Shao C, et al. JAMA Netw Open (2020) pmid: 33119110
10. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
11. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
12. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
13. Rizvi NA, et al. Science (2015) pmid: 25765070
14. Johnson BE, et al. Science (2014) pmid: 24336570
15. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
16. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
17. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
18. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
19. Nature (2012) pmid: 22810696
20. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
21. Li et al., 2021; AACR Abstract 2231
22. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
23. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
24. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
25. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
26. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
27. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
28. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
29. Lapin M, et al. J Transl Med (2018) pmid: 30400802
30. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
31. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
32. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
33. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
34. Fan G, et al. PLoS ONE (2017) pmid: 28187169
35. Vu et al., 2020; DOI: 10.1200/PO.19.00204
36. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
37. Zhang EW, et al. Cancer (2020) pmid: 32757294
38. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
39. Shaw RJ, et al. Cancer Cell (2004) pmid: 15261145
40. Ji H, et al. Nature (2007) pmid: 17676035
41. Contreras CM, et al. Cancer Res. (2008) pmid: 18245476
42. Gurumurthy S, et al. Cancer Res. (2008) pmid: 18172296
43. Shackelford DB, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19541609
44. Klümpen HJ, et al. J. Clin. Oncol. (2011) pmid: 21189378
45. Trédan O, et al. Target Oncol (2013) pmid: 23238879
46. Carretero J, et al. Cancer Cell (2010) pmid: 20541700
47. Skoulidis F, et al. Cancer Discov (2018) pmid: 29773717
48. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
49. Scheel AH, et al. Oncoimmunology (2016) pmid: 27467949
50. Skoulidis F, et al. Cancer Discov (2015) pmid: 26069186
51. Koyama S, et al. Cancer Res. (2016) pmid: 26833127
52. Schabath MB, et al. Oncogene (2016) pmid: 26477306
53. Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262
54. Kadara H, et al. Ann. Oncol. (2017) pmid: 27687306
55. Herter-Sprie GS, et al. JCI Insight (2016) pmid: 27699275
56. Skoulidis et al., 2017; IASLC 17th World Congress on Lung Cancer Abstract MA04.07
57. Jure-Kunkel et al., 2018; ASCO Abstract 3028
58. Stephens, 2017; AACR Abstract SY40-02
59. Skoulidis et al., 2015; ASCO Abstract 11002
60. Olschwang S, et al. J. Med. Genet. (2001) pmid: 11389158
61. Su GH, et al. Am. J. Pathol. (1999) pmid: 10362809
62. Sahin F, et al. Mod. Pathol. (2003) pmid: 12861065
63. Hu MT, et al. Int J Oncol (2018) pmid: 30015925
64. Wang J, et al. Oncotarget (2015) pmid: 26056085
65. Ollila S, et al. J Mol Cell Biol (2011) pmid: 21926085
66. Qiu W, et al. Oncogene (2006) pmid: 16407837
67. Mehenni H, et al. Am. J. Hum. Genet. (1998) pmid: 9837816
68. Karuman P, et al. Mol. Cell (2001) pmid: 11430832
69. Baas AF, et al. EMBO J. (2003) pmid: 12805220
70. Zeng PY, et al. Cancer Res. (2006) pmid: 17108107
71. Boudeau J, et al. J. Cell. Sci. (2004) pmid: 15561763
72. Scott KD, et al. Cancer Res. (2007) pmid: 17575127
73. Xie Z, et al. Mol. Cell. Biol. (2009) pmid: 19414597
74. Boudeau J, et al. Hum. Mutat. (2003) pmid: 12552571
75. Forcet C, et al. Hum. Mol. Genet. (2005) pmid: 15800014
76. Zhang L, et al. Sci Rep (2015) pmid: 25960268
77. Berger AH, et al. Cancer Cell (2016) pmid: 27478040
78. Amos CI, et al. J. Med. Genet. (2004) pmid: 15121768
79. Hearle N, et al. Clin. Cancer Res. (2006) pmid: 16707622
80. van der Groep P, et al. Cell Oncol (Dordr) (2011) pmid: 21336636
81. Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773
82. Prog Mol Biol Transl Sci (2011) pmid: 21507354
83. Yang J, et al. Mol Med Rep () pmid: 21887466
84. Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044
85. Daskalos A, et al. Cancer (2011) pmid: 21351083
86. Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317
87. Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581
88. Kim MS, et al. APMIS (2013) pmid: 23031157
89. Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382
90. Guo X, et al. Nature (2015) pmid: 25383530
91. Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090
92. Zhang ZM, et al. Nature (2018) pmid: 29414941
93. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
94. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
95. Xie M, et al. Nat. Med. (2014) pmid: 25326804
96. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
97. Severson EA, et al. Blood (2018) pmid: 29678827
98. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
99. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
100. Chabon JJ, et al. Nature (2020) pmid: 32269342
101. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
102. Owonikoko et al., 2016; ESMO Abstract 14230
103. Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631
104. Gong X, et al. Cancer Discov (2019) pmid: 30373917
105. Oser MG, et al. Cancer Discov (2019) pmid: 30373918
106. Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224
107. Allaman-Pillet N, et al. Ophthalmic Genet. () pmid: 21955141
108. Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955
109. Condorelli R, et al. Ann. Oncol. (2018) pmid: 29236940
110. Fry DW, et al. Mol. Cancer Ther. (2004) pmid: 15542782
111. Dean JL, et al. Oncogene (2010) pmid: 20473330
112. Dean JL, et al. Cell Cycle (2012) pmid: 22767154
113. Garnett MJ, et al. Nature (2012) pmid: 22460902
114. Roberts PJ, et al. J. Natl. Cancer Inst. (2012) pmid: 22302033
115. Patnaik A, et al. Cancer Discov (2016) pmid: 27217383
116. O'Leary B, et al. Cancer Discov (2018) pmid: 30206110
117. Costa C, et al. Cancer Discov (2019) pmid: 31594766
118. Chen SH, et al. Oncogene (2018) pmid: 29059158
119. Derenzini M, et al. Clin. Cancer Res. (2008) pmid: 18381962
120. Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056
121. Tarasen et al., 2014; USCAP Abstract 839
122. Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221
123. Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841
124. Berge EO, et al. Mol. Cancer (2010) pmid: 20594292
125. Giacinti C, et al. Oncogene (2006) pmid: 16936740
126. Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358
127. Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322
128. Qin XQ, et al. Genes Dev. (1992) pmid: 1534305
129. Rubin SM, et al. Cell (2005) pmid: 16360038
130. Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662
131. Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159
132. Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621
133. Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478
134. Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033
135. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
136. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
137. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
138. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
139. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
140. Xu L, et al. Mol. Med. (2001) pmid: 11713371
141. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
142. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
143. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
144. Hajdenberg et al., 2012; ASCO Abstract e15010
145. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
146. Moore et al., 2019; ASCO Abstract 5513
147. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
148. Oza et al., 2015; ASCO Abstract 5506
149. Lee J, et al. Cancer Discov (2019) pmid: 31315834
150. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
151. Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188
152. Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953
153. Mohell N, et al. Cell Death Dis (2015) pmid: 26086967
154. Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933
155. Gourley et al., 2016; ASCO Abstract 5571
156. Kwok M, et al. Blood (2016) pmid: 26563132
157. Boudny M, et al. Haematologica (2019) pmid: 30975914
158. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid:

Electronically signed by Lani Clinton, M.D., Ph.D. | 21 November 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

28062704
159. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
160. Li M, et al. Nat. Genet. (2014) pmid: 24997986
161. Ross JS, et al. Oncologist (2014) pmid: 24563076
162. Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509
163. Chan-On W, et al. Nat. Genet. (2013) pmid: 24185513
164. Borger DR, et al. Oncologist (2012) pmid: 22180306
165. Suto T, et al. J Surg Oncol (2000) pmid: 10738270
166. Ong CK, et al. Nat. Genet. (2012) pmid: 22561520
167. Javle M, et al. Cancer (2016) pmid: 27622582
168. Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283
169. Moreno M, et al. Ann Hepatol () pmid: 16177659
170. Won HS, et al. BMC Cancer (2010) pmid: 20955617
171. Chaube A, et al. BMC Cancer (2006) pmid: 16686942
172. Chuang SC, et al. World J Surg (2004) pmid: 15573254
173. Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940
174. Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750
175. Ajiki T, et al. Hepatogastroenterology () pmid: 8799388
176. J Surg Oncol (2006) pmid: 16724348
177. Guo R, et al. Hum. Pathol. (2014) pmid: 24746206
178. Boerner T, et al. Hepatology (2021) pmid: 33765338
179. Conci S, et al. Updates Surg (2020) pmid: 32020551
180. Simbolo M, et al. Sci Rep (2018) pmid: 29740198
181. Churi CR, et al. PLoS ONE (2014) pmid: 25536104
182. Lee CS, et al. Pathology (1995) pmid: 7567135
183. Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865
184. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
185. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
186. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
187. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
188. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
189. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
190. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
191. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
192. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
193. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
194. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
195. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
196. Lalloo F, et al. Lancet (2003) pmid: 12672316
197. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713